We have previously demonstrated that GSK126, a specific EZH2 inhibitor, exhibits anti-MM therapeutic efficacy and safetyin vivo andin vitro; however, its specific mechanism remains unclear. The gene discussed is EZH2; the disease is Miyoshi myopathy.